

# Donald N Forthal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/807568/publications.pdf>

Version: 2024-02-01

65  
papers

4,850  
citations

218381

26  
h-index

128067

60  
g-index

68  
all docs

68  
docs citations

68  
times ranked

5256  
citing authors

#	ARTICLE	IF	CITATIONS
1	Placebo-Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2005, 191, 654-665.	1.9	852
2	Fc receptor but not complement binding is important in antibody protection against HIV. <i>Nature</i> , 2007, 449, 101-104.	13.7	828
3	Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers. <i>PLoS Pathogens</i> , 2009, 5, e1000433.	2.1	475
4	Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector Cells. <i>Journal of Virology</i> , 2001, 75, 6953-6961.	1.5	208
5	Pharmaco-Immunomodulatory Therapy in COVID-19. <i>Drugs</i> , 2020, 80, 1267-1292.	4.9	208
6	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016, 22, 762-770.	15.2	197
7	Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate. <i>Journal of Immunology</i> , 2007, 178, 6596-6603.	0.4	169
8	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	2.1	145
9	Functions of Antibodies. <i>Microbiology Spectrum</i> , 2014, 2, AID-0019-2014.	1.2	139
10	Fc-Glycosylation Influences Fc $\gamma$ 3 Receptor Binding and Cell-Mediated Anti-HIV Activity of Monoclonal Antibody 2G12. <i>Journal of Immunology</i> , 2010, 185, 6876-6882.	0.4	138
11	Fc receptor-mediated antiviral antibodies. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 388-393.	1.5	130
12	Fc $\gamma$ RIIIa Genotype Predicts Progression of HIV Infection. <i>Journal of Immunology</i> , 2007, 179, 7916-7923.	0.4	124
13	Rhesus Macaque Polyclonal and Monoclonal Antibodies Inhibit Simian Immunodeficiency Virus in the Presence of Human or Autologous Rhesus Effector Cells. <i>Journal of Virology</i> , 2006, 80, 9217-9225.	1.5	87
14	The Neonatal Fc Receptor (FcRn) Enhances Human Immunodeficiency Virus Type 1 (HIV-1) Transcytosis across Epithelial Cells. <i>PLoS Pathogens</i> , 2013, 9, e1003776.	2.1	83
15	Relationship between Antibody-Dependent Cellular Cytotoxicity, Plasma HIV Type 1 RNA, and CD4+Lymphocyte Count. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 553-561.	0.5	76
16	Antibody-dependent cellular cytotoxicity in HIV infection. <i>Aids</i> , 2018, 32, 2439-2451.	1.0	67
17	HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2018, 24, 847-856.	15.2	65
18	Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: Complete protection of rhesus monkeys from mucosal SHIV challenge. <i>Vaccine</i> , 2015, 33, 2086-2095.	1.7	63

#	ARTICLE	IF	CITATIONS
19	Association of Fc $\gamma$ 3 receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. <i>Blood</i> , 2012, 120, 2836-2842.	0.6	57
20	Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.. <i>Drug Discovery Today</i> , 2021, 26, 593-603.	3.2	52
21	Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce $\beta$ -chemokines. <i>Journal of Experimental Medicine</i> , 2010, 207, 763-776.	4.2	51
22	Functions of Antibodies. <i>Microbiology Spectrum</i> , 2014, 2, 1-17.	1.2	50
23	Interactions between Natural Killer Cells and Antibody Fc Result in Enhanced Antibody Neutralization of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2005, 79, 2042-2049.	1.5	43
24	In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. <i>Journal of Immunological Methods</i> , 1998, 220, 129-138.	0.6	34
25	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. <i>Journal of Immunology</i> , 2016, 197, 2726-2737.	0.4	34
26	Antibody-Dependent Enhancement and the Risk of HIV Infection. <i>Current HIV Research</i> , 2013, 11, 421-426.	0.2	31
27	Impact of T <sub>H</sub> 1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	30
28	Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, e477-e486.	2.9	29
29	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. <i>Journal of Virology</i> , 2019, 93, .	1.5	25
30	IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. <i>Aids</i> , 2011, 25, 2099-2104.	1.0	24
31	Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. <i>Journal of Virology</i> , 2018, 92, .	1.5	24
32	Sex-Associated Differences in the Antibody-Dependent Cellular Cytotoxicity Antibody Response to Measles Vaccines. <i>Vaccine Journal</i> , 2000, 7, 111-113.	2.6	22
33	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. <i>Journal of Virology</i> , 2016, 90, 4133-4149.	1.5	22
34	Antibody-Dependent Cell-Mediated Virus Inhibition Antibody Activity Does Not Correlate With Risk of HIV-1 Superinfection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 31-33.	0.9	20
35	Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. <i>PLoS Pathogens</i> , 2017, 13, e1006793.	2.1	20
36	A Human Antibody to the CD4 Binding Site of gp120 Capable of Highly Potent but Sporadic Cross Clade Neutralization of Primary HIV-1. <i>PLoS ONE</i> , 2013, 8, e72054.	1.1	20

#	ARTICLE	IF	CITATIONS
37	Reopening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-Coronavirus 2019 Expectations, and Creative Solutions. <i>Journal of Pediatrics</i> , 2020, 223, 183-185.	0.9	15
38	A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens. <i>PLoS ONE</i> , 2015, 10, e0125581.	1.1	14
39	Chemically Modified Peptides Based on the Membrane-Proximal External Region of the HIV-1 Envelope Induce High-Titer, Epitope-Specific Nonneutralizing Antibodies in Rabbits. <i>Vaccine Journal</i> , 2014, 21, 1086-1093.	3.2	13
40	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. <i>Journal of Virology</i> , 2019, 93, .	1.5	13
41	How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?. <i>Transfusion</i> , 2022, , .	0.8	13
42	Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations. <i>Molecular Immunology</i> , 2016, 70, 94-103.	1.0	12
43	Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. <i>Journal of Virology</i> , 2019, 93, .	1.5	12
44	Enhanced In Vitro Transcytosis of Simian Immunodeficiency Virus Mediated by Vaccine-Induced Antibody Predicts Transmitted/Founder Strain Number After Rectal Challenge. <i>Journal of Infectious Diseases</i> , 2015, 211, 45-52.	1.9	11
45	Multimodality vaccination against clade C SHIV: Partial protection against mucosal challenges with a heterologous tier 2 virus. <i>Vaccine</i> , 2014, 32, 6527-6536.	1.7	9
46	Association of complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine. <i>Aids</i> , 2020, 34, 25-32.	1.0	9
47	Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy in COVID-19". <i>Drugs</i> , 2020, 80, 1501-1503.	4.9	8
48	Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	8
49	Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone. <i>Journal of Immunology</i> , 2021, 206, 1266-1283.	0.4	8
50	Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251. <i>Journal of Virology</i> , 2016, 90, 8487-8495.	1.5	7
51	HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. <i>PLoS ONE</i> , 2016, 11, e0160341.	1.1	7
52	Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. <i>Retrovirology</i> , 2021, 18, 35.	0.9	7
53	In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 354-360.	1.1	6
54	Adaptive immune responses to SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 1-8.	6.6	6

#	ARTICLE	IF	CITATIONS
55	Infection prevention strategies are highly protective in COVID-19 units while main risks to healthcare professionals come from coworkers and the community. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 163.	1.5	6
56	Blocking HIV-1 replication: are Fc $\alpha$ –Fc $\beta$ 3 receptor interactions required?. <i>Journal of Clinical Investigation</i> , 2018, 129, 53-54.	3.9	4
57	Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIV <sub>mac251</sub> Acquisition. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A64-A65.	0.5	3
58	CD46 Genetic Variability and HIV-1 Infection Susceptibility. <i>Cells</i> , 2021, 10, 3094.	1.8	3
59	Modulation of RAS Pathways as a Biomarker of Protection against HIV and as a Means to Improve Vaccine Efficacy. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A99-A99.	0.5	2
60	Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein. <i>PLoS ONE</i> , 2015, 10, e0133509.	1.1	0
61	COVID-19: An unprecedented challenge and an opportunity for change. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 48-49.	6.6	0
62	Internalization of HIV-1 by Phagocytes Is Increased When Virions Are Opsonized with Multimeric Antibody in the Presence of Complement. <i>Journal of Virology</i> , 2022, 96, JVI0168921.	1.5	0
63	306. Association of Antibiotic Use and Development Secondary Infection from <i>Clostridium difficile</i> , Multidrug-Resistant Bacteria, and <i>Candida</i> in Hospitalized Patients with History of COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, S259-S260.	0.4	0
64	Association between vaccine preventable diseases in children and improved sanitation following a nationwide sanitation campaign in India: an ecological analysis. <i>BMJ Open</i> , 2022, 12, e052937.	0.8	0
65	<i>IFNL4</i> genotype influences the rate of HIV-1 seroconversion in men who have sex with men. <i>Virulence</i> , 2022, 13, 757-763.	1.8	0